

In the claims:

Please cancel claims, without prejudice, claims 1-31 and add the following new claims:

- 21
- Sub B1
32. A composition of an improved anti-IgE antibody or IgE binding fragment in combination with an adjunct immunosuppressive agent, wherein the improved anti-IgE antibody or IgE binding fragment has at least one replaced aspartyl residue prone to isomerization replaced and wherein said improved anti-IgE antibody or IgE binding fragment has at least the same or greater affinity for IgE than the corresponding unimproved antibody or IgE binding fragment.
33. The composition of Claim 32 wherein the immunosuppressive agent is selected from the group consisting of 2-amino-5-aryl-substituted pyrimidines, azathioprine, cyclophosphamide, bromocryptine and glutaraldehyde.
34. The composition of Claim 32 wherein the immunosuppressive agent is selected from the group consisting anti-idiotypic antibodies which bind MHC antigens or fragments, cyclosporin A, glucocorticosteroids, cytokine antagonists and cytokine receptor antagonists.
35. The composition of Claim 32 wherein the immunosuppressive agent is an antibody selected from the group consisting of: anti-tumor necrosis factor- α ; anti-tumor necrosis factor- β ; anti-interleukin-2; antibodies; anti-L3T4; anti-lymphocyte globulin; anti-CD3; anti-CD4 and anti-CD4a.
36. The composition of Claim 32 wherein the immunosuppressive agent is an antibody selected from the group consisting of: a soluble peptide containing a LFA-3 binding domain; streptokinase; TGF- β ; streptodornase; deoxyspergualin; rapamycin, T-cell receptor and T cell receptor antibodies.
- Sub C3
37. The composition of Claim 32 wherein the improved anti-IgE antibody comprises the heavy and light chain sequences of e26 (SEQ ID NO:15-16).
38. The composition of Claim 32 wherein the improved IgE binding fragment comprises an E26 sequence selected from the group consisting of: an Fab fragment (SEQ ID NOs:19-20; an sFv fragment (SEQ ID NO:22) and an F(ab')₂ fragment (SEQ ID NOs: 24-25).